Why Is GINKGO BIOWORKS HLDG A (DNA) Stock Moving Today?

DNA stock is moving higher today, with shares up 4.5% as of 10:30 a.m. ET. The rise follows recent developments involving Ginkgo Bioworks’ collaboration with ProQR Therapeutics and broader biotech industry momentum. The stock has been volatile in recent months, trading between $5.37 and $17.58 over the past 52 weeks.

What Happened

Ginkgo Bioworks Holdings is seeing increased attention due to a recent partnership with ProQR Therapeutics, which provides access to Ginkgo’s 50+ instrument autonomous lab, Nebula. This collaboration supports ProQR’s research into genetic therapies, adding visibility to Ginkgo’s platform capabilities. Meanwhile, the broader biotech sector has seen movement, with companies like Estee Lauder and Moderna also rising on Wednesday.

Separately, Hanmi Pharm’s licensing deal with Genentech for a novel obesity therapy has drawn investor interest in the biotech space. While not directly tied to Ginkgo, the deal highlights ongoing momentum in therapeutic innovation. Ginkgo’s own Q2 earnings call, held recently, highlighted mixed results, balancing progress in platform development with continued financial pressure. The company reported Q1 earnings of $(1.39) per share, missing estimates, and revenue of $19.474 million also fell short of expectations.

What The Data Shows

DNA has a market cap of $498.3 million and remains unprofitable, with a trailing twelve-month net margin of -219.6%. The stock has declined 37.0% in revenue over the past year. On August 24, the stock printed 24 fresh 52-week lows, indicating ongoing pressure. Insiders have sold a total of $9,000 worth of shares in the last 90 days, with the most recent sale reported on July 20.

What To Watch

Ginkgo Bioworks does not have an upcoming earnings date in the near term, but coverage breadth and investor sentiment will remain key factors. Analysts have recently downgraded the stock, with TD Cowen lowering its price target to $9.